Checkpoint Therapeutics Inc. (NASDAQ: CKPT) Has Succeeded In Attracting Investors This Year, The Stock Is Up 31.32% Year-To-Date

Checkpoint Therapeutics Inc. (NASDAQ:CKPT)’s traded shares stood at 1.51 million during the last session, with the company’s beta value hitting 1.59. At the close of trading, the stock’s price was $3.48, to imply a decrease of -5.95% or -$0.22 in intraday trading. The CKPT share’s 52-week high remains $5.38, putting it -54.6% down since that peak but still an impressive 36.78% since price per share fell to its 52-week low of $2.20. The company has a valuation of $292.18M, with average of 730.47K shares over the past 3 months.

Analysts have given a consensus recommendation of a Buy for Checkpoint Therapeutics Inc. (CKPT), translating to a mean rating of 1.80. Of 5 analyst(s) looking at the stock, 0 analyst(s) give CKPT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.14.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


After registering a -5.95% downside in the last session, Checkpoint Therapeutics Inc. (CKPT) has traded red over the past five days. The stock hit a weekly high of 4.35 this Thursday, 11/18/21, dropping -5.95% in its intraday price action. The 5-day price performance for the stock is -18.69%, and 10.83% over 30 days. With these gigs, the year-to-date price performance is 31.32%.

Analysts on Wall Street suggest a consensus price target of $15.80, implying an increase of 77.97% to the stock’s current value. The extremes give us $8.00 and $20.00 for target low and target high price respectively. As such, CKPT has been trading -474.71% off suggested target high and -129.89% from its likely low.

Checkpoint Therapeutics Inc. (CKPT) estimates and forecasts

Revenue is forecast to shrink -55.60% this quarter before jumping 11.80% for the next one. The rating firms project that company’s revenue will shrink -44.80% compared to the previous financial year.

Revenue forecast for the current quarter as set by 5 analysts is $120k. Meanwhile, for the quarter ending Dec 2021, a total of 5 analyst(s) estimate revenue growth to $180k.Earnings reports from the last fiscal year show that sales brought in $28k and $27k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 328.60% before jumping 566.70% in the following quarter.

CKPT Dividends

Checkpoint Therapeutics Inc. has its next earnings report out between August 03 and August 09. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Checkpoint Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Checkpoint Therapeutics Inc. (NASDAQ:CKPT)’s Major holders

Checkpoint Therapeutics Inc. insiders hold 16.66% of total outstanding shares, with institutional holders owning 21.81% of the shares at 26.17% float percentage. In total, 21.81% institutions holds shares in the company, led by Blackrock Inc. As of Mar 30, 2021, the company held over 3.54 million shares (or 12.28% of shares), all amounting to roughly $11.13 million.

The next major institution holding the largest number of shares is Opaleye Management Inc. with 2.93 million shares, or about 10.14% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $9.19 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Checkpoint Therapeutics Inc. (CKPT) shares. Going by data provided on Mar 30, 2021, Vanguard Total Stock Market Index Fund holds roughly 1.45 million shares. This is just over 5.02% of the total shares, with a market valuation of $4.55 million. Data from the same date shows that the other fund manager holds a little less at 1.28 million, or 4.43% of the shares, all valued at about 3.42 million.